<DOC>
	<DOCNO>NCT00153049</DOCNO>
	<brief_summary>1 . To investigate dose response combination therapy , Telmisartan Hydrochlorothiazide Japanese patient Essential Hypertension . 2 . To compare dose response US study .</brief_summary>
	<brief_title>3 x 3 Factorial Trial Telmisartan Hydrochlorothiazide Patients With Essential Hypertension</brief_title>
	<detailed_description>This 8-week multicentre , randomise , double-blind , double-dummy , placebo-controlled , parallel group study utilizing cell 3 x 3 factorial design . Following Screening examination 4-week Placebo Run-In Period , 540 patient randomized receive once-daily monotherapy either telmisartan ( MICARDIS ) , hydrochlorothiazide , placebo , combination therapy telmisartan hydrochlorothiazide 8 week ( Treatment Period ) . This study include nine cell , placebo , telmisartan ( TEL ) 40 mg , TEL 80 mg , hydrochlorothiazide ( HCTZ ) 6.25 mg , HCTZ 12.5 mg , TEL 40 mg/HCTZ 6.25 mg , TEL 40 mg/HCTZ 12.5 mg , TEL 80 mg/HCTZ 6.25 mg , TEL 80 mg/HCTZ 12.5 mg. Study Hypothesis : The hypothesis dose response model Japanese patient essential hypertension construct change supine diastolic blood pressure baseline value end treatment multiple regression analysis , similar US study 502.204 . Comparison ( ) : The primary efficacy parameter change baseline supine diastolic blood pressure trough ( 24 hour post-dose ) last visit Double-Blind Period . The dose response surface model construct . The graph dose response surface generate base final model . The model study compare US study perspective include term model .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Telmisartan , hydrochlorothiazide drug combination</mesh_term>
	<criteria>1 . Essential hypertensive patient meet follow criterion : Mean supine DBP &gt; = 95 &lt; = 114 mm Hg Visits 2 3 . Mean supine DBP must vary 10 mm Hg Visit 2 Visit 3 . Mean supine systolic blood pressure ( SBP ) must &gt; = 140 &lt; = 200 mm Hg Visit 3 . ( The mean DBP SBP value calculate mean three supine measurement take two minute apart . ) 2 . Male female . 3 . Age &gt; = 20 Age &lt; = 80 year . 4 . Outpatient . 5 . Able stop current antihypertensive therapy without risk patient . 6 . Ability provide write Informed Consent accordance ? Good Clinical Practice ( GCP ) ? ( MHW Ordinance No . 28 , Mar . 27 , 1997 ) local legislation . 1 . Known suspected secondary hypertension ( renovascular hypertension , primary aldosteronism , melanocytoma , etc. ) . 2 . Mean supine DBP &gt; 114 mmHg and/or mean supine SBP &gt; 200 mmHg visit placebo runin period . 3 . Sustained ventricular tachycardia clinically relevant cardiac arrhythmia ( atrioventricular conduction disturbance ( grade II III ) , atrial fibrillation etc. ) . 4 . NYHA functional class heart failure IIIIV . 5 . Myocardial infarction cardiac surgery within 6 month sign informed consent form . 6 . Coronary artery bypass surgery percutaneous transluminal coronary angioplasty ( PTCA ) within 3 month sign informed consent form . 7 . Unstable angina within 3 month sign informed consent form . 8 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve . 9 . Stroke transient ischemic attack within 6 month sign informed consent form . 10 . History sudden exacerbation renal function AT1 receptor antagonist ACE inhibitor ; postrenal transplant . 11 . Patients previously experience characteristic symptom angioedema ( facial , tongue , pharyngeal , laryngeal swell dyspnea ) treatment AT1 receptor antagonist ACE inhibitor . 12 . Known hypersensitivity component formulation , know hypersensitivity sulfonamide sulphonamidederived drug ( e.g . thiazide ) . 13 . Hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( ALT ) SGOT ( AST ) &gt; = 2 time upper limit normal screening ( Visit 1 ) . Patients markedly poor bile secretion follow laboratory parameter : Patients whose direct bilirubin &gt; = 2.0 mg/dL screening ( Visit 1 ) . Serum creatinine &gt; = 2.1 mg/dL screening ( Visit 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>